Advancing Prostate Cancer Outcomes Through Big Data
A public-private partnership under the Innovative Medicines Initiative (IMI) bringing together academia and industry.
Aimed to improve outcomes and care for prostate cancer patients through the use of big data and real-world evidence.
Developed a comprehensive data platform integrating clinical, genomic, and patient-reported data across Europe.
Established a federated data infrastructure to securely analyse prostate cancer datasets across multiple institutions and countries.
Defined core outcome sets for prostate cancer, emphasizing outcomes that matter most to patients.
Developed tools and evidence that directly feed into EAU Guidelines and decision-making pathways.
Following the end of the IMI funding period, PIONEER+ sustainability arm ensures the continued use and expansion of:
Data models and ontologies for prostate cancer research and clinical practice.
Federated analytics tools built for multi-institutional collaboration and secure data sharing.
Outcome standardization frameworks, including PROMs for consistent measurement across studies.
Training, governance, and open science initiatives to support the research community.
Researchers and clinicians across Europe can continue using PIONEER+ tools and models to drive meaningful insights.
PIONEER+ data continues to inform the development and refinement of EAU clinical guidelines.
The PIONEER+ infrastructure is not a finished project—it's a living foundation for future discovery and improvement in prostate cancer care.
Discover the full scope of PIONEER+ contributions to prostate cancer research and clinical practice.
Utilize PIONEER+ validated tools and frameworks for measuring prostate cancer outcomes in your practice.
Join the collaborative network and contribute to the next generation of prostate cancer research.
All PIONEER+ innovations are now being maintained and evolved within the UEH ecosystem, supporting ongoing innovation and clinical application.
Contact: datainnovation@uroweb.org
PIONEER+ was supported by the Innovative Medicines Initiative (IMI) under grant agreement No 777492.
Sustainability and ongoing development are now managed through the EAU UroEvidenceHub.